

## Clearbridge marks entry to Indonesia healthcare market with acquisition of a renal care services provider

- *Completes acquisition of a controlling stake in PT Tirta Medika Jaya for approximately S\$5.5 million*

**SINGAPORE – 23 April 2018 – Clearbridge Health Limited** (“Clearbridge” or the “Company” and together with its subsidiaries, the “Group”) (明策集团), a healthcare company listed on the Catalist Board of the Singapore Exchange Securities Trading Limited with a focus on the delivery of precision medicine in Asia, has completed the acquisition of a controlling stake in PT Tirta Medika Jaya (“PT Tirta”), paving the way for the Group to expand its business in Indonesia

PT Tirta provides renal care services by partnering with medical device equipment manufacturers and hospitals. Through joint operation agreements with hospitals, PT Tirta operates renal dialysis facilities co-located with partnering hospitals and to-date has a network comprising 15 facilities across Indonesia.

The aggregate consideration of S\$5.5 million comprises S\$3.30 million in cash, S\$1.09 million satisfied by the allotment and issuance of new ordinary shares in the capital of Clearbridge while S\$1.11 million is payable upon PT Tirta achieving certain target earnings before interest expense, income taxes, depreciation and amortisation. This is in line with the Group’s commitment to optimise its capital structure to enhance shareholder value while expanding its businesses in a sustainable and prudent manner.

**Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge,** said: *“We look forward to a mutually rewarding partnership with PT Tirta. The Group is buying into a profitable business that supports our growth plans to expand our medical clinics and medical centres business regionally. We will work with them to leverage their existing network of hospital partners to deliver the Group’s precision medicine products and services in Indonesia so as to achieve positive and more targeted clinical outcomes and better care for patients.”*

This marks Clearbridge’s third acquisition since its initial public offering in December 2017. The first was a Philippine healthcare services provider, Marzan Health Care Inc., followed by a medical and aesthetics clinic in Singapore operating under the name Medic Surgery and Laser Clinic.

-- END --

### **About Clearbridge Health Limited**

Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises laboratory testing services, medical clinics/centres and strategic equity participation in complementary precision medical technology companies. Through the delivery of precision medicine in Asia, it seeks to empower clinicians and healthcare professionals to make more reliable and



accurate diagnoses, provide insights to disease management, and tailor personalised prevention and timely treatment programmes for patients. For more information, please visit us at [www.clearbridgehealth.com](http://www.clearbridgehealth.com).

*Issued by and on behalf of Clearbridge Health Limited*

**August Consulting**

Tel: +65 6733 8873

Silvia Heng, [silviaheng@august.com.sg](mailto:silviaheng@august.com.sg)

Wrisney Tan, [wrisneytan@august.com.sg](mailto:wrisneytan@august.com.sg)

Zavier Ong, [zavierong@august.com.sg](mailto:zavierong@august.com.sg)

*This press release has been prepared by the Company and its contents have been reviewed by the Company's sponsor, United Overseas Bank Limited (the "Sponsor"), for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST").*

*The Sponsor has not independently verified the contents of this press release. This press release has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.*

*The contact person for the Sponsor is Mr Chia Beng Kwan, Senior Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.*